VLN3G2細(xì)胞
運(yùn)輸方式： 凍存運(yùn)輸
細(xì)胞形態(tài)： **樣
**類型： IgG4
生長狀態(tài)： 懸浮生長
數(shù)量： 大量
ATCC Number： HB-8636?
是否是腫瘤細(xì)胞： 0
物種來源： 人
Designations: VLN3G2
Depositors: Regents of the University of California
Isotype: IgG4
VLN3G2細(xì)胞Biosafety Level: 2 [CELLS CONTAIN HERPESVIRUS ]
Shipped: frozen
Medium & Serum: See Propagation
Growth Properties: suspension
Organism: human (B cell); human (myeloma)
Morphology: lymphoblast
Source: Cell Type: hybridoma: B lymphocyte;
Cellular Products: immunoglobulin; monoclonal antibody; against cancer of the vulva
Permits/Forms: In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. VLN3G2細(xì)胞Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Comments: Lymphocytes were isolated from a regional draining lymph node of a patient with carcinoma of the vulva.
B lymphocytes were fused with UC 729-6 cells (see ATCC CRL-8061).
The antibody recognizes an epitope on a 78000 dalton antigen on A-431 cells and a 66000 dalton antigen on T293H cells.
Propagation: ATCC complete growth medium: VLN3G2細(xì)胞The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Temperature: 37.0°C
Subculturing: Protocol: Cultures can be maintained by the addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 1 X 10 exp5 viable cells/ml. Maintain cell density between 1 X 10 exp5 and 5 X 10 exp5 viable cells/ml.
Medium Renewal: Every 2 days
Preservation: VLN3G2細(xì)胞Freeze medium: Complete growth medium 95%; DMSO, 5%
Storage temperature: liquid vapor phase
Related Products: Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2001
recommended serum:ATCC 30-2020
References: 21921: Glassy MC, Surh C. Human-human hybrid cell lines that produce antibodies against antigenic determinants on cancer cells. US Patent 4,761,377 dated Aug 2 1988
